ArticleJournal for immunotherapy of cancer2023
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis.
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 60 citations in OpenAlex.
- Tissue-derived extracellular matrix hydrogels instruct epigenetic adaptation in metastatic colonization.Bioactive materials · 2027Article
- Manganese-potentiated cGAS-STING activation with ATM/PRMT5 inhibition remodels the immunosuppressive microenvironment in osteosarcomaBioactive materials · 2026Article
- Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.Materials today. Bio · 2026Article
- Programming Mn(II) coordination in self-assembling peptides amplifies mtDNA-driven STING signaling for potent antitumor immunity.Materials today. Bio · 2026Article
- DNA-damage-targeting copper nanoparticles induce cuproptosis for enhanced cancer radiotherapy.Materials today. Bio · 2026Article
- Rational design of a V-shaped DNA-targeted photosensitizer enables endogenous DNA damage-driven cGAS-STING activation and systemic antitumor immunity.Materials today. Bio · 2026Article
- Dual-functional catalytic photothermal immunological agent for ferroptosis induction and cGAS-STING pathway activation: Enhancing tumor immunotherapy and generating robust immune memory.Materials today. Bio · 2026Article
- Degradable STING nanomodulators orchestrate the innate-to-adaptive immune response for NIR-II photothermal-immunotherapy via a cancer-immunity cycle.Materials today. Bio · 2026Article
- Non-coding RNAs as master regulators of ferroptosis in cancer: mechanisms and clinical implications.Molecular cancer · 2026Review
- Extracellular Vesicles in Myocardial Infarction: Dual Role in Ferroptosis Regulation and In Vivo Imaging.Diagnostics (Basel, Switzerland) · 2026Review
- An exosome-biomimetic photothermal nanocarrier for IGF2BP2 siRNA delivery and enhanced ferroptosis in head and neck squamous cell carcinoma.Materials today. Bio · 2026Article
- Apoptotic body-encapsulated zinc-dopedMaterials today. Bio · 2026Article
- Biomimetic nanoplatform with multienzyme cascade activity boosting ROS generation and immune activation feedback for tumor therapy.Materials today. Bio · 2026Article
- Copper/iron-based intelligent nanoparticles self-amplify apoptosis/ferroptosis/cuproptosis in colorectal cancer.Materials today. Bio · 2026Article
- Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application.Experimental hematology & oncology · 2026Review
- Innovative Pathways in Burn Treatment: Exosomes and the New Era of Regenerative Medicine.International journal of nanomedicine · 2026Review
- Ferroptosis and the eye: bridging the gap between cell death and vision preservation.Frontiers in immunology · 2026Review
- Engineered Exosomes: Advances in Therapeutic Applications for Otolaryngology-Head and Neck Diseases.International journal of nanomedicine · 2026Review
- Review
- Transferrin conjugated pH/NIR-responsive black phosphorus nanoplatform: A novel multimodal approach for breast cancer theranostics.International journal of pharmaceutics: X · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunosuppressive tumor microenvironment (ITM) remains an obstacle that jeopardizes clinical immunotherapy.
methodsTo address this concern, we have engineered an exosome inherited from M1-pheototype macrophages, which thereby retain functions and ingredients of the parent M1-phenotype macrophages. The delivered RSL3 that serves as a common ferroptosis inducer can reduce the levels of ferroptosis hallmarkers (eg, glutathione and glutathione peroxidase 4), break the redox homeostasis to magnify oxidative stress accumulation, promote the expression of ferroptosis-related proteins, and induce robust ferroptosis of tumor cells, accompanied with which systematic immune response activation can bbe realized. M1 macrophage-derived exosomes can inherit more functions and genetic substances than nanovesicles since nanovesicles inevitably suffer from substance and function loss caused by extrusion-arised structural damage.
resultsInspired by it, spontaneous homing to tumor and M2-like macrophage polarization into M1-like ones are attained, which not only significantly magnify oxidative stress but also mitigate ITM including M2-like macrophage polarization and regulatory T cell decrease, and regulate death pathways.
conclusionsAll these actions accomplish a synergistic antitumor enhancement against tumor progression, thus paving a general route to mitigate ITM, activate immune responses, and magnify ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.